CD24 (heat stable antigen or nectadrin) is a GPI-linked, highly glycosylated, dynamically expressed molecule present on cells of the immune system, myeloid cells (including granulocytes), keratinocytes, adipocytes, and also on astrocytes, microglia and neurons ().
The biological functions of CD24 cover a wide spectrum largely due to the nature and extent of glycosylation. CD24 lacks an intracellular signaling domain, but interestingly shows a superior ability to co-localize with, and organize, a wide range of cell surface molecules into lipid rafts associated with signaling pathways (). Expression of CD24 is largely differentiation-associated, for example, it is most highly expressed on early lymphocyte progenitors and on neuronal cells during neurogenesis and regeneration ().
In B cell development, CD24 expression was first used a marker for pre-B cells in fetal liver and bone marrow (), and subsequently has become one of the main CD markers for staging B cell development (). CD24 is high on progenitor B cells with slightly lower expression on immature B cells followed by a sharp decease at the naive stage. CD24 is re-expressed but with different functional properties on memory B cells. The signaling properties of CD24 change during B cell development, being linked to pro-apoptotic pathways in pre-B cells but not at later stages (ā). Moreover, Mensah etĀ al. previously showed a clear increase in CD24 expression in both naĆÆve and memory IgD+B cell populations in the circulation of individuals with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) ().
In primary bone marrow B cells and B cell lines, CD24 increases the release of extracellular vesicles, which are able to transfer signalling competent receptors to recipient B cells (ā). In cultured memory B cells, there is a link between CD24 expression and energy metabolism (glucose consumption) and with the metabolic stress response (pAMPK), and possibly senescence, in pre-switch memory B cells (). CD24 is notably absent from mature plasma cells due to the dependence of niche occupancy on the interaction between CXCR4 (CD184) in lipid rafts on plasma cells and pro-survival signaling via C-X-C chemokine ligand 12 (CXCL12, SDF-1) in the bone marrow (). CD24 expression excludes CXCR4 from lipid rafts so loss of CD24 is essential to allow access of developing B cells and mature plasma cells to supportive niches.
In the context of malignancy, CD24 expression is widespread, being expressed on approximately 70% of solid tumours and often associated with increased metastatic potential and poor prognosis (). CD24 is, thus, useful for non-invasive fluorescence imaging, allowing improved tumour resection and as a focus for targeted therapy. When highly expressed on tumour cells, CD24 transmits a ādo not eat meā signal via Sigleg-10 receptors on macrophages; an in trans interaction between the two cell types (). Therefore, as well as the possibility of targeting CD24 expressed on tumours using cytotoxic anti-CD24 biologics, the use of āblockingā antibodies to CD24 could also be used as an enhancing agent for immunotherapy ().
CD24 can also differentiate between the damage associated molecular pattern (DAMP) response through binding to released self-proteins, eg. HMGB-1 and heat shock proteins, but not pathogen associated molecular patterns (PAMPs) (, ). Specifically, binding to released HMGB-1 and heat shock proteins allows co-localisation, in cis, with Sigleg-10 in dendritic cells. This triggers the downregulation of proinflammatory signalling via the Src homology 2 domain-containing phosphatase 1 (SHP)-Sigleg-10 pathway. The soluble molecule complexed with Fc fragment of IgG (CD24Fc), therefore, can block or blunt a broad inflammatory response leading to CD24Fc being used in several contexts including severe COVID-19 infection and autoinflammatory diseases (, ).
Under this Research Topic, there are two review articles and two original research articles. Liu and Zheng's review article focuses on the interactions between CD24 and Siglecs. CD24 is GPI-linked and, therefore, it must interact with a partner in cis to mediate signal transduction in the host cell. The authors review the literature demonstrating that CD24 functions via the CD33 family of Siglec proteins in various cell types. In particular, the observation that CD24 functions via Siglec-G/10 to inhibit the dendritic cell response to DAMPs and not PAMPs is highlighted as this paved the way for therapeutic targeting of CD24 via the CD24Fc protein to moderate immune activation. They then discuss the role of CD24 in autoimmune disorders and metabolic function.
In the second review article, Gu etĀ al. discuss the association of CD24 with ovarian cancer. In ovarian cancer, increased CD24 expression is associated with increased metastasis and poorer survival. As the authors discuss, one reason for this observation may be because of the role CD24 plays in immune evasion via the ādonāt eat meā signal towards macrophages. The authors finish by discussing other potential roles for CD24 in directly regulating ovarian cancer growth and progression.
In the original research article by Zhang etĀ al. it was demonstrated that expression of CD24 on dendritic cells contributed to priming of T cells. Specifically, they showed that in the absence of CD24, adoptively transferred murine T cells do not undergo sufficient expansion and exhibit increased cell death. This phenotype was rescued when CD24 was re-expressed on dendritic cells.
Lastly, Armstrong etĀ al. found that upon in vitro activation with T-dependent or Toll-like-receptor 9 (TLR)-dependent agonists CD24 expression on B cells from ME/CFS patients had a delayed decrease, consistent with in vivo results. Additional metabolomic studies further confirmed an association of CD24 with B cell metabolism, namely a correlation with glucose usage and lactate production. B cells from ME/CFS patients also had significantly higher uptake of amino acids, which has been associated with an increased degradation of nucleotides to AMP perhaps showing a possible link with fatigue in patients with ME/CFS. Thus, alterations in CD24 expression may potentially be useful in exploring B cell immunometabolism.
This Research Topic provides a window into the diverse functions of CD24 as well as increasing our knowledge of how CD24 directly regulates immune and innate cell interactions with tumour cells and contributes to T cell priming. Moreover, CD24 may also be linked with immunometabolism, particularly in B cells.
Statements
Author contributions
SC: Writing ā original draft, Writing ā review & editing. GC: Writing ā original draft, Writing ā review & editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisherās note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AyreDCChristianSL. CD24: A rheostat that modulates cell surface receptor signaling of diverse receptors. Front Cell Dev Biol. (2016) 4:146. doi:Ā 10.3389/fcell.2016.00146
2
FangXZhengPTangJLiuY. CD24: from A to Z. Cell Mol Immunol. (2010) 7:100ā3. doi:Ā 10.1038/cmi.2009.119
3
BofillMJanossyGJanossaMBurfordGDSeymourGJWernetPet al. Human B cell development. II. Subpopulations in the human fetus. J Immunol. (1985) 134:1531ā8. doi:Ā 10.4049/jimmunol.134.3.1531
4
HardyRRHayakawaK. B cell development pathways. Annu Rev Immunol. (2001) 19:595ā692. doi:Ā 10.1146/annurev.immunol.19.1.595
5
SuzukiTKiyokawaNTaguchiTSekinoTKatagiriYUFujimotoJ. CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol. (2001) 166:5567ā77. doi:Ā 10.4049/jimmunol.166.9.5567
6
TaguchiTKiyokawaNMimoriKSuzukiTSekinoTNakajimaHet al. Pre-B cell antigen receptor-mediated signal inhibits CD24-induced apoptosis in human pre-B cells. J Immunol. (2003) 170:252ā60. doi:Ā 10.4049/jimmunol.170.1.252
7
LuLChappelMSHumphriesRKOsmondDG. Regulation of cell survival during B lymphopoiesis: increased pre-B cell apoptosis in CD24-transgenic mouse bone marrow. Eur J Immunol. (2000) 30:2686ā91. doi:Ā 10.1002/1521-4141(200009)30:9<2686::AID-IMMU2686>3.0.CO;2-F
8
MensahFBansalABerkovitzSSharmaAReddyVLeandroMJet al. Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study. Clin Exp Immunol. (2016) 184:237ā47. doi:Ā 10.1111/cei.12749
9
AyreDCElstnerMSmithNCMooresESHoganAMChristianSL. Dynamic regulation of CD24 expression and release of CD24-containing microvesicles in immature B cells in response to CD24 engagement. Immunology. (2015) 146:217ā33. doi:Ā 10.1111/imm.12493
10
AyreDCChuteICJoyAPBarnettDAHoganAMGruelMPet al. CD24 induces changes to the surface receptors of B cell microvesicles with variable effects on their RNA and protein cargo. Sci Rep. (2017) 7:8642. doi:Ā 10.1038/s41598-017-08094-8
11
PhanH-DLongjohnMNGormleyDJBSmithRHDang-LawsonMMatsuuchiLet al. CD24 and IgM stimulation of B cells triggers transfer of functional B cell receptor to B cell recipients via extracellular vesicles. J Immunol. (2021) 207:3004ā15. doi:Ā 10.4049/jimmunol.2100025
12
MensahFFKArmstrongCWReddyVBansalASBerkovitzSLeandroMJet al. CD24 expression and B cell maturation shows a novel link with energy metabolism: potential implications for patients with myalgic encephalomyelitis/chronic fatigue syndrome. Front Immunol. (2018) 9:2421. doi:Ā 10.3389/fimmu.2018.02421
13
SchabathHRunzSJoumaaSAltevogtP. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci. (2006) 119:314ā25. doi:Ā 10.1242/jcs.02741
14
AltevogtPSammarMHüserLKristiansenG. Novel insights into the function of CD24: A driving force in cancer. Int J Cancer. (2021) 148:546ā59. doi:Ā 10.1002/IJC.33249
15
BarkalAABrewerREMarkovicMKowarskyMBarkalSAZaroBWet al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. (2019) 572:392ā6. doi:Ā 10.1038/s41586-019-1456-0
16
ChristianSL. CD24 as a potential therapeutic target in patients with B-cell leukemia and lymphoma: current insights. OncoTargets Ther. (2022) 15:1391ā402. doi:Ā 10.2147/OTT.S366625
17
ChenGYTangJZhengPLiuY. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. (2009) 323:1722ā5. doi:Ā 10.1126/science.1168988
18
ChenGYChenXKingSCavassaniKAChengJZhengXet al. Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol. (2011) 29:428ā35. doi:Ā 10.1038/nbt.1846
19
SongNJAllenCVilgelmAERiesenbergBPWellerKPReynoldsKet al. Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. J Hematol Oncol. (2022) 15:5. doi:Ā 10.1186/s13045-021-01222-y
20
BaiXFLiuJQLiuXGuoYCoxKWenJet al. The heat-stable antigen determines pathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitis. J Clin Invest. (2000) 105:1227ā32. doi:Ā 10.1172/JCI9012
Summary
Keywords
CD24, ovarian cancer, Siglec, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), T cell priming, immune evasion
Citation
Christian SL and Cambridge G (2024) Editorial: CD24 in the regulation of cellular development and disease. Front. Immunol. 15:1374701. doi: 10.3389/fimmu.2024.1374701
Received
22 January 2024
Accepted
20 February 2024
Published
27 February 2024
Volume
15 - 2024
Edited and reviewed by
Subbarao Bondada, University of Kentucky, United States
Updates
Copyright
Ā© 2024 Christian and Cambridge.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sherri L. Christian, sherri.christian@mun.ca; Geraldine Cambridge, g.cambridge@ucl.ac.uk
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.